BR112019008824A2 - derivados heterocíclicos bicíclicos substituídos úteis como inibidores de canal de romk - Google Patents

derivados heterocíclicos bicíclicos substituídos úteis como inibidores de canal de romk

Info

Publication number
BR112019008824A2
BR112019008824A2 BR112019008824A BR112019008824A BR112019008824A2 BR 112019008824 A2 BR112019008824 A2 BR 112019008824A2 BR 112019008824 A BR112019008824 A BR 112019008824A BR 112019008824 A BR112019008824 A BR 112019008824A BR 112019008824 A2 BR112019008824 A2 BR 112019008824A2
Authority
BR
Brazil
Prior art keywords
bicyclic heterocyclic
derivatives useful
substituted bicyclic
heterocyclic derivatives
channel inhibitors
Prior art date
Application number
BR112019008824A
Other languages
English (en)
Inventor
Gunaga Prashantha
Bhide Rajeev
Onkardas Bora Rajesh
Panda Manoranjan
Dnyanoba Yadav Navnath
Scott Priestley Eldon
Richter Jeremy
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BR112019008824A2 publication Critical patent/BR112019008824A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

a invenção refere-se a compostos de fórmula (i) (i) ou um sal dos mesmos, em que r1 é: ou ; cada w é independentemente nr1b ou o; z é uma ligação ou chr1d; e r1, r2, rd, r3, l1, l2, r1a, r1b, r1c, e n são definidos aqui. da mesma forma descritos são os métodos de usar tais compostos como inibidores de romk, e composições farmacêuticas compreendendo tais compostos. estes compostos são úteis no tratamento de doenças cardiovasculares.
BR112019008824A 2016-11-03 2017-11-02 derivados heterocíclicos bicíclicos substituídos úteis como inibidores de canal de romk BR112019008824A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201611037609 2016-11-03
PCT/US2017/059642 WO2018093569A1 (en) 2016-11-03 2017-11-02 Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors

Publications (1)

Publication Number Publication Date
BR112019008824A2 true BR112019008824A2 (pt) 2019-07-09

Family

ID=60413273

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019008824A BR112019008824A2 (pt) 2016-11-03 2017-11-02 derivados heterocíclicos bicíclicos substituídos úteis como inibidores de canal de romk

Country Status (14)

Country Link
US (1) US10723723B2 (pt)
EP (1) EP3535258B1 (pt)
JP (1) JP7102404B2 (pt)
KR (1) KR102530512B1 (pt)
CN (1) CN110139862B (pt)
AU (1) AU2017362870A1 (pt)
BR (1) BR112019008824A2 (pt)
CA (1) CA3042380A1 (pt)
EA (1) EA201991095A1 (pt)
ES (1) ES2902527T3 (pt)
IL (1) IL266326A (pt)
MX (1) MX2019004999A (pt)
SG (1) SG11201903871TA (pt)
WO (1) WO2018093569A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019024950A2 (pt) 2017-06-01 2020-06-23 Bristol-Myers Squibb Company Compostos contendo nitrogênio substituído
EP3935050A4 (en) 2019-03-06 2023-01-04 C4 Therapeutics, Inc. HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT
JP2023550591A (ja) 2020-11-02 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032074B2 (ja) 1980-06-25 1985-07-25 芦森工業株式会社 管路
CN100564375C (zh) * 2002-04-03 2009-12-02 阿勒根公司 作为激酶抑制剂的(3z)-3-(2,3-二氢-1h-茚-1-叉)-1,3-二氢-2h-吲哚-2-酮
EP1620108B1 (en) * 2003-05-01 2012-06-06 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
EP1628661A2 (en) * 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
WO2007117465A2 (en) * 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
PL2463283T3 (pl) 2006-04-20 2014-10-31 Pfizer Prod Inc Skondensowane fenyloamidowe związki heterocykliczne do zapobiegania i leczenia chorób pośredniczonych przez glukokinazę
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
JP5575646B2 (ja) 2007-08-27 2014-08-20 アボット ゲーエムベーハー ウント カンパニー カーゲー ４−（４−ピリジニル）−ベンズアミドおよびｒｏｃｋ活性調節因子としてのこれらの使用
PT2310012E (pt) 2008-06-30 2015-04-02 Janssen Pharmaceutica Nv Processo para a preparação de derivados de pirimidina substituída
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2010127855A1 (en) 2009-05-07 2010-11-11 Grünenthal GmbH Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands
AU2010247391A1 (en) 2009-05-15 2011-12-01 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
EP2536690B1 (en) 2010-02-19 2018-08-08 Arizona Board Of Regents Multifunctional radical quenchers and their use
WO2012058116A1 (en) 2010-10-27 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2632464B1 (en) 2010-10-29 2015-04-29 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AU2012299227A1 (en) 2011-08-19 2014-02-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2755656B1 (en) 2011-09-16 2016-09-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2771004B1 (en) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062892A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
WO2013066718A2 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773206B1 (en) 2011-10-31 2018-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9206199B2 (en) 2011-12-16 2015-12-08 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2647628A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Substituted tricyclic compounds with activity towards ep1 receptors
EA201492069A1 (ru) 2012-05-30 2015-03-31 Ф.Хоффманн-Ля Рош Аг Соединения триазола в качестве ингибиторов фосфодиэстеразы 10 (pde10)
WO2014015495A1 (en) 2012-07-26 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
NZ705096A (en) 2012-08-21 2018-02-23 Peter Maccallum Cancer Inst Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof
WO2014085210A1 (en) 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014099633A2 (en) 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9604998B2 (en) 2013-02-18 2017-03-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2968288B1 (en) 2013-03-15 2018-07-04 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9777872B2 (en) 2013-07-05 2017-10-03 Jeffrey Scott Adler Fluid spill containment, location, and real time notification device with cable based sensor
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9951052B2 (en) * 2013-10-31 2018-04-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US10000484B2 (en) * 2013-12-18 2018-06-19 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassim channel
WO2015090579A1 (en) 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
WO2015096035A1 (en) 2013-12-24 2015-07-02 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2015103756A1 (en) 2014-01-09 2015-07-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016008064A1 (en) 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
MX2017000634A (es) 2014-07-14 2017-05-01 Merck Sharp & Dohme Inhibidores del canal de potasio medularmente externo renal.
WO2016060941A1 (en) 2014-10-14 2016-04-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065582A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065603A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016069428A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065602A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
MX2017006536A (es) 2014-12-08 2017-08-09 Jiangsu Hengrui Medicine Co Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos.
CN105693706B (zh) 2014-12-10 2019-11-22 江苏恒瑞医药股份有限公司 异苯并呋喃酮类衍生物、其制备方法及其在医药上的应用
US10513518B2 (en) 2015-01-29 2019-12-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
JP6905993B2 (ja) 2016-04-20 2021-07-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換された二環式ヘテロ環化合物
BR112019024950A2 (pt) 2017-06-01 2020-06-23 Bristol-Myers Squibb Company Compostos contendo nitrogênio substituído

Also Published As

Publication number Publication date
WO2018093569A4 (en) 2018-07-12
US20190248769A1 (en) 2019-08-15
MX2019004999A (es) 2019-08-05
EA201991095A1 (ru) 2019-09-30
EP3535258A1 (en) 2019-09-11
CN110139862A (zh) 2019-08-16
AU2017362870A1 (en) 2019-06-20
WO2018093569A1 (en) 2018-05-24
SG11201903871TA (en) 2019-05-30
IL266326A (en) 2019-06-30
ES2902527T3 (es) 2022-03-28
US10723723B2 (en) 2020-07-28
JP7102404B2 (ja) 2022-07-19
KR102530512B1 (ko) 2023-05-08
CN110139862B (zh) 2024-01-16
JP2020504706A (ja) 2020-02-13
EP3535258B1 (en) 2021-11-24
KR20190075110A (ko) 2019-06-28
CA3042380A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
CY1121144T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
BR112018001650A2 (pt) compostos de heteroarila ou arila fundidos bicíclicos como moduladores de irak4
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
BR112017013677A2 (pt) compostos macrocíclicos como inibidores de irak1/4 e usos dos mesmos
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
BR112019004248A2 (pt) inibidores da dopamina-b-hidroxilase
EA201892264A1 (ru) Производные тетрагидроизохинолина
EA201692300A1 (ru) Производные карбоксамида
EA201890448A1 (ru) Фумагиллиновые спироциклические соединения и конденсированные бициклические соединения и способы их получения и применения
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2694 DE 23-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.